Safety and Efficacy Triple Drug Therapy (IDA) versus Two-drug therapy DA in Lymphatic Filariasis: A Systematic Review
DOI:
https://doi.org/10.53770/amhj.v5i3.602Keywords:
Lymphatic, Filiariasis, Mass Drug Administration, Elephantiasis, IvermecetinAbstract
Lymphatic filariasis (elephantiasis) is a parasitic disease caused by Wuchereria bancrofti, Brugia malayi, and Brugia timori, and is transmitted through the bite of infected mosquitoes. This disease is classified as a neglected tropical disease and has been targeted for global elimination through mass drug administration strategies. This systematic review aimed to evaluate the safety and effectiveness of a single-dose triple-drug therapy consisting of ivermectin, diethylcarbamazine, and albendazole (IDA) compared with the two-drug regimen of diethylcarbamazine and albendazole (DA) based on randomized clinical trials. A literature search was conducted in PubMed using the keyword “elephantiasis,” yielding eleven relevant studies published within the last five years. The results indicated that moderate adverse events occurred more frequently with IDA therapy, although most were mild in nature, while serious adverse events were more commonly reported with DA therapy. No significant differences were observed in filarial antigen levels between the groups. IDA therapy was well tolerated and considered as safe as DA, while demonstrating greater effectiveness in clearing microfilariae. With high coverage of mass drug administration, widespread use of IDA has the potential to accelerate the elimination of lymphatic filariasis.
References
Astuti, E. P., Hendri, J., Ipa, M., Ruliansyah, A., & Garjito, T. A. (2023). Vector surveillance for lymphatic filariasis after mass drug administration in an endemic area: A case study in Bekasi. Jurnal Kesehatan Lingkungan, 15(2), 134–142. https://doi.org/10.20473/jkl.v15i2.2023.134-142
Azhar, S., Abdullah, M. N., Qamar, W., Iqbal, M. J., Asghar, S., Ajaz, R., ... & Khalid, A. (2023). Basic insights into lymphatic filariasis. Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan, 2, 73-88. https://doi.org/10.47278/book.zoon/2023.53
Babu, S., & Nutman, T. B. (2012). Immunopathogenesis of lymphatic filarial disease. Seminars in Immunopathology, 34(6), 847–861. https://doi.org/10.1007/s00281-012-0346-4
Bagonza, A., Gibson, L., Kabiri, L., Bezalel, C., Narahari, S. R. B., Franks, P. J., ... & Moffatt, C. (2025). Exploring barriers to accessing treatment for Lymphatic Filariasis through a socio-ecological lens in Buvuma and Napak districts, Uganda. PLOS Neglected Tropical Diseases, 19(1), e0012747. https://doi.org/10.1371/journal.pntd.0012747
Debrah, A. Y., Mand, S., Specht, S., Marfo-Debrekyei, Y., Batsa, L., Pfarr, K., Larbi, J., Lawson, B., Taylor, M., Adjei, O., & Hoerauf, A. (2006). Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathogens, 2(9), e92. https://doi.org/10.1371/journal.ppat.0020092
Dubray, C. L., Sircar, A. D., de Rochars, V. M. B., Bogus, J., Direny, A. N., Ernest, J. R., Fayette, C. R., Goss, C. W., Hast, M., O’Brien, K., Pavilus, G. E., Sabin, D. F., Wiegand, R. E., Weil, G. J., & Lemoine, J. F. (2020). Safety and efficacy of co-administered diethylcarbamazine, albendazole, and ivermectin during mass drug administration for lymphatic filariasis in Haiti. PLoS Neglected Tropical Diseases, 14(6), e0008298. https://doi.org/10.1371/journal.pntd.0008298
Goss, C. W., O’Brien, K., Dubray, C., Fischer, P. U., Hardy, M., Jambulingam, P., King, C. L., Laman, M., Lemoine, J. F., Robinson, L. J., Samuela, J., Subramanian, S., Supali, T., Weil, G. J., & Schechtman, K. B. (2019). Dosing pole recommendations for lymphatic filariasis elimination. PLoS Neglected Tropical Diseases, 13(7), e0007541. https://doi.org/10.1371/journal.pntd.0007541
Gyapong, J. O., Owusu, I. O., da-Costa Vroom, F. B., Mensah, E. O., & Gyapong, M. (2018). Elimination of lymphatic filariasis: Current perspectives on mass drug administration. Research and Reports in Tropical Medicine, 9, 25–33. https://doi.org/10.2147/RRTM.S125204
Irvine, M. A., Stolk, W. A., Smith, M. E., Subramanian, S., Singh, B. K., Weil, G. J., Michael, E., & Hollingsworth, T. D. (2017). Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: A modelling study. The Lancet Infectious Diseases, 17(4), 451–458. https://doi.org/10.1016/S1473-3099(16)30467-4
King, C. L., Suamani, J., Sanuku, N., Cheng, Y.-C., Satofan, S., Mancuso, B., Goss, C. W., Robinson, L. J., Siba, P. M., Weil, G. J., & Kazura, J. W. (2018). A trial of a triple-drug treatment for lymphatic filariasis. New England Journal of Medicine, 379(19), 1801–1810. https://doi.org/10.1056/NEJMoa1706854
Krentel, A., Basker, N., de Rochars, M. B., Bogus, J., Direny, A. N., Dubray, C., Fischer, P. U., Goss, C. W., Hardy, M., Jambulingam, P., King, C. L., Lemoine, J. F., Robinson, L. J., Samuela, J., & Weil, G. J. (2021). Acceptability of a triple-drug regimen for elimination of lymphatic filariasis. PLoS Neglected Tropical Diseases, 15(3), e0009002. https://doi.org/10.1371/journal.pntd.0009002
Lee, J., & Ryu, J. S. (2019). Current status of parasite infections in Indonesia. Korean Journal of Parasitology, 57(4), 329–339. https://doi.org/10.3347/kjp.2019.57.4.329
Medeiros, Z. M., Vieira, A. V. B., Xavier, A. T., Bezerra, G. S. N., Lopes, M. F. C., Bonfim, C. V., & Aguiar-Santos, A. M. (2022). Lymphatic filariasis morbidity: A systematic review. International Journal of Environmental Research and Public Health, 19(1), 316. https://doi.org/10.3390/ijerph19010316
Sinha, A., Kumar, S., Dayal, D., Yadav, V., Pramanik, A., Chaubey, K. K., & Kumar, S. (2023). Elimination of lymphatic filariasis: Where do we stand so far?. Asian Pacific Journal of Tropical Medicine, 16(9), 385-399. https://doi.org/10.4103/1995-7645.380729
Tan, M., Kusriastuti, R., Savioli, L., & Hotez, P. J. (2014). Indonesia: An emerging market economy beset by neglected tropical diseases. PLoS Neglected Tropical Diseases, 8(2), e0002449. https://doi.org/10.1371/journal.pntd.0002449
Ton, T. G. N., Mackenzie, C., & Molyneux, D. H. (2015). The burden of mental health in lymphatic filariasis. Infectious Diseases of Poverty, 4(1), 34. https://doi.org/10.1186/s40249-015-0068-7
Weil, G. J., Bogus, J., Christian, M., Dubray, C., Djuardi, Y., Fischer, P. U., ... & DOLF IDA Safety Study Group. (2019). The safety of double-and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLoS medicine, 16(6), e1002839. https://doi.org/10.1371/journal.pmed.1002839
World Health Organization. (2010). Lymphatic filariasis: Progress report 2000–2009 and strategic plan 2010–2020. Geneva: World Health Organization. Retrieved from: https://www.who.int/publications/i/item/9789241500722
World Health Organization. (2020). Lymphatic filariasis: Reporting continued progress towards elimination as a public health problem. Geneva: World Health Organization. Retrieved from: https://www.who.int/news/item/29-10-2020-lymphatic-filariasis-reporting-continued-progress-towards-elimination-as-a-public-health-problem
Yadav, A., Yadav, S., & Alam, A. (2024). A Landscape on Lymphatic Filariasis with its Effects and Recent Advanced Treatments. Recent Advances in Anti-Infective Drug Discovery Formerly Recent Patents on Anti-Infective Drug Discovery, 19(3), 197-215. https://doi.org/10.2174/0127724344266902231117112109
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ahmar Metastasis Health Journal
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
